Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Thursday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Up 5.1 %

Shares of NYSE:OGEN opened at $0.42 on Thursday. The company’s fifty day moving average is $0.85 and its two-hundred day moving average is $1.22. The company has a market cap of $1.88 million, a P/E ratio of -0.05 and a beta of 0.45. Oragenics has a 12-month low of $0.38 and a 12-month high of $7.74.

Oragenics (NYSE:OGEN) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent SEC filing. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.